5,7-二氟吲哚-2-甲酸 | 186432-20-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5,7-二氟吲哚-2-甲酸
• 英文名称: 5,7-Difluoro-1H-indole-2-carboxylic acid
• CAS: 186432-20-2
• 化学式: C₉H₅F₂NO₂
• mdl: MFCD01863161
• 分子量: 197.14
• InChiKey: WVZUEYDXSLBMEK-UHFFFAOYSA-N

物化性质

• 熔点：
  264 °C (decomp)
• 沸点：
  414.7±40.0 °C(Predicted)
• 密度：
  1.605±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  53.1
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  5,7-二氟吲哚-2-甲酸 、 (S)-2-amino-1-(4-hydroxy-piperidin-1-yl)-3-phenyl-propan-1-one 生成 (S)-5,7-Difluoro-1H-indole-2-carboxylic acid [1-benzyl-2-(4-hydroxy-piperidin-1-yl)-2-oxo-ethyl]-amide
  参考文献：
  名称：

  Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as

  摘要：

  公式（1）中R.sub.6为羧基，（C.sub.1-C.sub.8）烷氧羰基，苄氧羰基，C（O）NR.sub.8 R.sub.9或C（O）R.sub.12的化合物作为糖原磷酸化酶抑制剂，含有这种抑制剂的制药组合物以及使用这种抑制剂治疗哺乳动物的糖尿病，高血糖，高胆固醇血症，高血压，高胰岛素血症，高脂血症，动脉粥样硬化和心肌缺血。

  公开号：

  US06107329A1

文献信息

• 1,3-substitued cycloalkyl derivatives having acidic, mostly heterocyclic groups; processes for their preparation and their use as pharmaceuticals
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040209932A1

  公开（公告）日：2004-10-21

  The invention relates to 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistence is involved.

  本发明涉及具有酸性、大多数是杂环基团的1,3-取代环烷衍生物及其生理上可接受的盐和生理上功能衍生物。所描述的是式I中的化合物，其中基团如定义所示，以及它们的生理上可接受的盐和制备它们的过程。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍以及胰岛素抵抗涉及的疾病。
• [EN] SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS<br/>[FR] (INDOLE-2-CARBONYL-)-GLYCINAMIDES SUBSTITUES EN N ET LEURS DERIVES, SERVANT D'INHIBITEURS DE LA GLYCOGENE PHOSPHORYLASE
  申请人：PFIZER, INC.

  公开号：WO1996039384A1

  公开（公告）日：1996-12-12

  (EN) Compounds of Formula (1) wherein R6 is carboxy, (C1-C8)alkoxycarbonyl, benzyloxycarbonyl, C(O)NR8R9 or C(O)R12 as glucogen phosphorylase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals.(FR) L'invention concerne des composés de formule (1) où R6 représente carboxy, alcoxycarbonyle (C1-C8), benzyloxycarbonyle, C(O)NR8R9 ou C(O)R12, servant d'inhibiteurs de la glycogène phosphorylase, ainsi que des compositions pharmaceutiques contenant ces inhibiteurs. L'invention concerne également l'utilisation de ces inhibiteurs pour le traitement du diabète, de l'hyperglycémie, de l'hypercholestérolémie, de l'hypertension, de l'hyperinsulinémie, de l'hyperlipidémie, de l'athérosclérose et de l'ischème myocardiaque chez les mammifères.

  化合物的化学式为(1)，其中R6代表羧基、(C1-C8)烷氧羰基、苄氧羰基、C(O)NR8R9或C(O)R12，作为糖原磷酸化酶抑制剂，含有这种抑制剂的制药组合物以及使用这种抑制剂治疗哺乳动物的糖尿病、高血糖、高胆固醇血症、高血压、高胰岛素血症、高脂血症、动脉粥样硬化和心肌缺血的方法。
• Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors
  申请人：Pfizer, Inc.

  公开号：US06277877B1

  公开（公告）日：2001-08-21

  Compounds of Formula (I) wherein R6 is carboxy, (C1-C8)alkoxycarbonyl, benzyloxycarbonyl, C(O)NR8R9 or C(O)R12 as glycogen phosphorylase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperisulinemia, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals.

  化合物公式(I)中， R6为羧基，(C1-C8)烷氧羰基，苄氧羰基，C(O)NR8R9或C(O)R12，作为糖原磷酸化酶抑制剂，制备含有此类抑制剂的制药组合物，并将此类抑制剂用于治疗哺乳动物的糖尿病，高血糖，高胆固醇血症，高血压，高胰岛素血症，高脂血症，动脉粥样硬化和心肌缺血。
• 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES HAVING ACIDIC, MOSTLY HETEROCYCLIC GROUPS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
  申请人：Goerlitzer Jochen

  公开号：US20080249126A1

  公开（公告）日：2008-10-09

  The invention relates to 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved.

  本发明涉及具有酸性、大多数为杂环基团的1,3-取代环烷衍生物及其生理上可接受的盐和生理上功能性衍生物。所描述的是式I的化合物，其中基团如定义所述，以及它们的生理上可接受的盐和制备它们的方法。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用紊乱以及涉及胰岛素抵抗的紊乱。
• 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups, processes for their preparation and their use as pharmaceuticals
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US08048901B2

  公开（公告）日：2011-11-01

  The invention relates to 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved.

  本发明涉及具有酸性、大多数为杂环基团的1,3-取代环烷衍生物及其生理上可接受的盐和生理上功能衍生物。所描述的化合物为公式I中的基团所定义，以及它们的生理上可接受的盐和制备它们的过程。这些化合物适用于治疗和/或预防脂肪酸代谢和葡萄糖利用障碍以及胰岛素抵抗相关的疾病。